Baloncibart lowers orthostatic tachycardia in phase 2 POTS data
Regeneron Pharmaceuticals has posted positive phase 2 results for baloncibart in postural orthostatic tachycardia syndrome, a disorder that can turn the simple act of standing into a physiologic stress test. The data move the antibody closer to a potentially pivotal phase 3 trial, now expected to begin in the first half of 2027.
POTS is defined by an abnormal rise in heart rate after a patient stands up from sitting or lying down. The syndrome can produce palpitations, dizziness and lightheadedness in the upright position, but its burden extends well beyond those classic orthostatic symptoms. Fatigue, exercise intolerance, cognitive complaints, gastrointestinal symptoms and chronic pain often persist between posture changes, making the disease both hemodynamic and systemic in day-to-day practice.
Regeneron built its development strategy around an NPR1-blocking mechanism. The company’s working hypothesis is straightforward: inhibiting NPR1 may increase circulating blood volume and reduce the compensatory tachycardia that defines the disorder. In POTS, even modest improvements in intravascular volume can alter the autonomic response to standing, easing the heart’s need to overcompensate when venous return falls.
Day 8 and Day 29 separated the doses
The phase 2 Pinnacle study randomized 82 patients with POTS to receive either one of two doses of baloncibart or placebo. The 450 mg dose met the trial’s primary endpoint, producing an 11.4 beats per minute lower change in heart rate from lying down to standing compared with placebo at Day 8. By Day 29, the difference remained 7.4 bpm. The 150 mg dose also beat placebo at Day 8, but the effect was no longer apparent by Day 29.
A one-time physiologic signal can be encouraging, but durability carries more weight in a chronic autonomic disorder.
The separation between the two dose levels suggests a real exposure-response relationship rather than a class-wide placebo wobble. In a syndrome shaped by unstable preload and exaggerated sympathetic compensation, a treatment that preserves a reduction in orthostatic tachycardia over several weeks is clinically more meaningful than a brief early effect. The higher dose appears to have cleared that bar; the lower dose did not.
Regeneron also reported accompanying symptom changes that track with the heart-rate findings. At Day 29, symptoms linked to standing improved in the 450 mg arm versus placebo, and patients also performed better on assessments of physical functioning and activities of daily living. The 150 mg dose did not show obvious improvement over placebo on these measures. For a patient population that often struggles with ordinary upright activity, those functional endpoints matter because they move beyond a purely numeric pulse reduction and into what patients can actually do after standing.
Biomarker shifts fit the blood-volume hypothesis
The physiologic pattern extended beyond heart rate. On Day 8, biomarker changes aligned with baloncibart’s expected effect on blood volume, and standing systolic blood pressure rose on both doses. In the 450 mg cohort, standing systolic blood pressure increased by 8.7 mmHg to a mean of 118.8 mmHg at Day 29. That change is consistent with a treatment that may be improving circulatory reserve, not merely blunting a reflex.
The biological logic is important here. If blood volume improves, the body does not need to trigger as dramatic a compensatory tachycardia upon standing, and symptoms tied to cerebral hypoperfusion and autonomic overdrive may ease in parallel. This is the kind of mechanism that can translate into both hemodynamic and functional benefit when it holds over time.
George Yancopoulos, M.D., Ph.D., Regeneron’s chief scientific officer, previously framed the findings as improvements that appear linked to durable restoration of intravascular volume. The company now views the signal as strong enough to justify a larger study, and the phase 3 program is slated for the first half of 2027.
Safety was not the limiting factor in the phase 2 readout
Treatment-emergent adverse events were more common with baloncibart than with placebo, affecting 67.9% of patients in the 450 mg arm versus 48.1% in the control group. The events were mostly mild or moderate, and none led to treatment discontinuation.
For a disorder with no FDA-approved therapy, tolerability will remain central when the program moves into a broader trial. POTS patients are often young or middle-aged and may already be living with fluctuating symptoms, so a safety profile that avoids treatment-limiting toxicity matters as much as raw efficacy. A therapy that improves standing hemodynamics but forces patients off drug would not meet the practical demands of this disease.
Regeneron’s phase 3 plans arrive in a field with limited industry attention. No approved treatments exist for POTS, and few sponsored development programs are active. Argenx and CSL Behring previously ran trials in patients who developed POTS after COVID-19 infection, but those programs are no longer active.
The unmet need is large. Regeneron has said POTS affects between 500,000 and several million people in the U.S., and most patients are women. The condition is also frequently underdiagnosed, which means many patients never reach a specialist or a trial site before the disorder becomes a prolonged source of disability.
A phase 3 trial will need to prove more than pulse control
The next study will have to confirm that the heart-rate reduction seen in Pinnacle translates into sustained symptom relief across a larger and more varied population. It will also need to show that the blood-volume hypothesis holds up when exposure is extended and when the trial population is large enough to capture the heterogeneity that defines POTS in routine care.
The phase 2 readout gives Regeneron a cleaner development path than most programs in this space have managed to achieve. The 450 mg dose separated from placebo on the main physiologic endpoint, held that advantage at Day 29, and improved standing-related symptoms and function. The lower dose did not maintain the same pattern, which makes dose selection for phase 3 much easier.
What remains unresolved is how broadly that benefit will generalize across the syndrome’s different clinical phenotypes, and whether the hemodynamic gains will prove sufficient to change daily life over longer follow-up. The next trial will need to answer those questions without assuming that a favorable phase 2 signal is enough on its own.